Share tips of the week – 20 August
MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
Three to buy
Ocean Outdoor
(The Mail on Sunday) Outdoor advertising “had limited appeal” in 2020: turnover at ad agency Ocean Outdoor fell by 28% to £86m. But the firm “used the year wisely, bedding down 2019 acquisitions, renegotiating contracts with landlords and investing in the future”. Demand is recovering quickly and profits of £14.5m are expected next year, with “substantial gains” pencilled in for the years to come. The firm specialises in digital advertising, one of the fastest-growing subsectors $8.38
Serco
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
(Investors’ Chronicle) The Covid-19 Test & Trace contract made up 17% of public-sector outsourcing group Serco’s revenues and led to a 31% increase in operating profit in the first half of 2021. Sales are expected to be lower in the second half of the year as Covid-19 “dissipates”, but the company believes “the goodwill it has built up will stand it in good stead”. The firm has a strong balance sheet, which offers protection. The company acquired US defence business Whitney, Bradley & Brown in February, which bodes well as the US defence budget is unlikely to be cut. 140p
London Stock Exchange Group
(Shares Magazine) The stock has swooned since March; investors are fretting over the cost of integrating data provider Refinitiv, acquired for $27bn. But interim results bode well. Pre-tax profits almost doubled to £510m. The deal with Refinitiv “enhances exposure” to subscription- based revenues and secures the firm’s position in Asia and America. The group boasts “unique... market infrastructure and data assets”. 7,812p
Three to sell
Palantir
(InvestorPlace) US software group Palantir “is a wonderful company”, but it is trading at an inflated price. The company does well when it comes to securing contracts with agencies of the US federal government, but growing its client base in the private sector “has been a work in progress”. The stock is on a forward price/earnings (p/e) ratio of 175. Even if it fell by 50%, its valuation would “more than [reflect] its growth prospects”. Avoid for now. $24.90
Capita
(Investors’ Chronicle) “Ever-shrinking outsourcer Capita enjoyed a reasonable half compare with its usual dreadful standards.” The company expects to “finally see sustainable free cash flow in 2022”. But for now, it is “bleeding cash” thanks partly to pension payments and restructuring costs. The firm disposed of £536m worth of assets in the first half, but the fire sale was due to the fast-approaching “wall of maturing short-term debt”. Like most other outsourcers, the firm’s assumptions on government spending “have been proved consistently wrong”, which has led to “troublesome and underperforming contracts”. Sell. 37p
Randall & Quilter
(The Daily Telegraph) It is not clear whether Aim-listed insurer Randall & Quilter qualifies for inheritance-tax (IHT) relief. The crux of the matter is the nature of the firm’s assets (“passively” held investments are not eligible for IHT relief, whereas “trading” assets needed to keep the company running are). R&Q insists its shares qualify, but HMRC may disagree. If you opted for R&Q for the IHT relief, sell and reinvest in another Aim stock. 170p
...and the rest
The Daily Telegraph
Shares in Fastned, the Dutch operator of fast-charging electric car stations, have fallen by 40% since February. That is probably due to the “unwinding” of some “speculative money” that went into renewables; there is no sign of trouble at the company. Hold (€60). MaxCyte, the “futuristic” gene-therapy company, has long-term potential. Last month’s listing on the Nasdaq raised $202m for research and development. Hold (1,105p).
Mail on Sunday
Flooring group James Halstead marked almost half a century of unbroken growth last year, which reflects the group’s culture of “financial conservatism and product innovation”. It boasts schools, stations, offices, shops, homes and hospitals as customers, and “virtually every NHS trust uses its flooring”. The stock should keep repaying shareholders “handsomely”. Hold (550p).
Investors’ Chronicle
Zetefoams is a specialist in cellular-materials technology, or foam. The company is struggling with “significant supply-chain inflationary pressures”. But they were either brought on by the pandemic or exacerbated by it, so they should eventually dissipate. Hold (449p).
Shares Magazine
Elective procedures are returning as Covid-19 ebbs. Demand for medical-equipment firm Boston Scientific’s products is picking up again. The group reported second-quarter profit and sales that surpassed expectations, and it has raised its full-year outlook. The stock has risen by 24% in 2021 and there should be further gains ahead. Buy ($43.81).
Sign up to Money Morning
Our team, led by award winning editors, is dedicated to delivering you the top news, analysis, and guides to help you manage your money, grow your investments and build wealth.
-
Most affordable towns to buy a home in the UK
Zoopla research reveals parts of the UK where house price-to-earnings ratios are better for buyer budgets
By Marc Shoffman Published
-
Investing in pharmaceutical companies? The pipeline is key
A strong pipeline is all-important for pharmaceutical companies. We highlight the most interesting candidates.
By Dr Mike Tubbs Published
-
DCC: a top-notch company going cheap
DCC has a stellar long-term record and promising prospects. It has been unfairly marked down
By Jamie Ward Published
-
How investors can use options to navigate a turbulent world
Explainer Options can be a useful solution for investors to protect and grow their wealth in volatile times.
By James Proudlock Published
-
Will platinum and palladium rise?
Analysis Platinum and palladium have lagged gold and silver recently, but the outlook is improving. Should you invest?
By David J. Stevenson Published
-
Invest in Hilton Foods: a tasty UK food supplier
Hilton Foods is a keenly priced opportunity in an unglamorous sector
By Dr Matthew Partridge Published
-
HSBC stocks jump – is its cost-cutting plan already paying off?
HSBC's reorganisation has left questions unanswered, but otherwise the banking sector is in robust health
By Dr Matthew Partridge Published
-
Lock in an 11% yield with Sabre
Tips Sabre, a best-in-class company is undervalued due to low profits in the motor insurance industry. Should you invest?
By Rupert Hargreaves Published
-
James Halstead is a family firm going cheap but should you buy?
James Halstead will rebound from a weak patch, while tax changes would be a buying opportunity
By Jamie Ward Published
-
Babcock: an overlooked defence investment
Defence stocks have outperformed this year, but Babcock has been left behind
By Oojal Dhanjal Published